Eline J. Willemse

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 69 publications

Evolution of blood biomarkers reflective of brain tissue damage and inflammation in the perioperative course of intracerebral haemorrhage evacuation in a phase II proof-of-concept trial.

Evolution of blood biomarkers reflective of brain tissue damage and inflammation in the perioperative course of intracerebral haemorrhage evacuation in a phase II proof-of-concept trial.

Journal: BMJ open
Published: June 25, 2026

Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and Beyond.

Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and Beyond.

Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: April 23, 2026

Proinflammatory Epstein-Barr Virus Antibody Functions Track with Disease Activity in Multiple Sclerosis.

Proinflammatory Epstein-Barr Virus Antibody Functions Track with Disease Activity in Multiple Sclerosis.

Journal: Annals of neurology
Published: January 13, 2026

Serum GFAP as a biomarker for progression in multiple sclerosis: assay comparison and a large reference database of healthy controls.

Serum GFAP as a biomarker for progression in multiple sclerosis: assay comparison and a large reference database of healthy controls.

Journal: Clinical chemistry and laboratory medicine
Published: November 08, 2025

Comparative analysis of three platforms for serum NfL quantification in healthy controls and MS patients.

Comparative analysis of three platforms for serum NfL quantification in healthy controls and MS patients.

Journal: Clinical chemistry and laboratory medicine
Published: November 07, 2025

Switching from anti-CD20 therapies to cladribine and vice versa - Analysis of a German relapsing multiple sclerosis cohort.

Switching from anti-CD20 therapies to cladribine and vice versa - Analysis of a German relapsing multiple sclerosis cohort.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: September 08, 2025

GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.

GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.

Journal: Brain : a journal of neurology
Published: June 14, 2025

GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.

GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.

Journal: Brain : a journal of neurology
Published: June 14, 2025

Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis.

Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis.

Journal: Brain : a journal of neurology
Published: May 12, 2025

Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis.

Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis.

Journal: Brain : a journal of neurology
Published: May 12, 2025

Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response.

Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response.

Journal: Annals of clinical and translational neurology
Published: April 01, 2025

A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders.

A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders.

Journal: Nature medicine
Published: March 21, 2025
Showing 1-12 of 69

Last Updated: 09/26/2026